Key Points
- EVP Kevin Waters sold 6,721 shares on March 6 at an average price of $23.70 for about $159,288, trimming his stake to 152,264 shares (a 4.23% decrease).
- Director Antal Rohit Desai purchased roughly $10.5 million of stock March 5–9, boosting his holdings to 426,262 shares — a notable bullish insider signal that contrasts the EVP sales.
- PROCEPT missed Q4 estimates with ($0.53) EPS and $76.38M revenue versus $93.7M expected, and two law firms have opened securities‑fraud investigations, creating a short‑term negative catalyst.
PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Get Free Report) EVP Kevin Waters sold 6,721 shares of the company's stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $23.70, for a total value of $159,287.70. Following the completion of the transaction, the executive vice president owned 152,264 shares in the company, valued at $3,608,656.80. This represents a 4.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
PROCEPT BioRobotics Price Performance
NASDAQ PRCT opened at $25.26 on Tuesday. The company has a debt-to-equity ratio of 0.14, a current ratio of 6.85 and a quick ratio of 5.77. The firm has a market capitalization of $1.42 billion, a price-to-earnings ratio of -14.77 and a beta of 1.03. The company has a 50 day simple moving average of $29.11 and a 200-day simple moving average of $32.83. PROCEPT BioRobotics Corporation has a 52-week low of $19.35 and a 52-week high of $66.85.
PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last announced its quarterly earnings data on Wednesday, February 25th. The company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.21). The company had revenue of $76.38 million for the quarter, compared to analysts' expectations of $93.70 million. PROCEPT BioRobotics had a negative net margin of 31.02% and a negative return on equity of 25.13%. The business's revenue for the quarter was up 11.9% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.35) earnings per share. Equities research analysts predict that PROCEPT BioRobotics Corporation will post -1.75 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd lifted its stake in shares of PROCEPT BioRobotics by 436.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company's stock valued at $29,000 after purchasing an additional 746 shares during the last quarter. JTC Employer Solutions Trustee Ltd bought a new stake in PROCEPT BioRobotics in the third quarter worth $30,000. Center for Financial Planning Inc. acquired a new position in PROCEPT BioRobotics during the fourth quarter worth $40,000. Vega Investment Solutions increased its position in PROCEPT BioRobotics by 52.0% during the second quarter. Vega Investment Solutions now owns 775 shares of the company's stock worth $45,000 after buying an additional 265 shares during the last quarter. Finally, US Bancorp DE raised its holdings in PROCEPT BioRobotics by 175.7% during the third quarter. US Bancorp DE now owns 1,693 shares of the company's stock valued at $60,000 after buying an additional 1,079 shares in the last quarter. Institutional investors own 89.46% of the company's stock.
More PROCEPT BioRobotics News
Here are the key news stories impacting PROCEPT BioRobotics this week:
- Positive Sentiment: Director Antal Rohit Desai completed a series of large open‑market purchases March 5–9, increasing his stake to 426,262 shares; the three Form 4 filings show roughly $10.5M of insider buying over those days — a strong bullish signal that executives view the stock as undervalued. Insider Purchase Filings
- Positive Sentiment: Research coverage was initiated at Robert W. Baird, which can increase visibility and trading interest (Baird’s note content/rating not included in the filing). Research Coverage Started at Robert W. Baird
- Neutral Sentiment: Two senior executives (EVPs Kevin Waters and Alaleh Nouri) sold small stakes (6,721 and 6,892 shares respectively on March 6) for a combined ~13.6k shares (~$322k), likely personal liquidity rather than a company signal given the scale relative to the director’s purchases. Kevin Waters Sale Filing Alaleh Nouri Sale Filing
- Negative Sentiment: Two law firms (Levi & Korsinsky and Schall) announced securities‑fraud investigations related to PROCEPT’s prior guidance and statements (citing prior revenue targets and handpiece pricing comments). Such investigations raise the risk of litigation, distraction and potential disclosures or restatements — a clear negative catalyst for sentiment. Levi & Korsinsky Investigation Notice Schall Law Firm Investigation Notice
Wall Street Analyst Weigh In
A number of equities analysts have recently weighed in on PRCT shares. Oppenheimer reaffirmed a "market perform" rating on shares of PROCEPT BioRobotics in a research note on Thursday, February 26th. UBS Group started coverage on PROCEPT BioRobotics in a research report on Friday, December 12th. They set a "buy" rating and a $62.00 price objective for the company. TD Cowen dropped their target price on PROCEPT BioRobotics from $50.00 to $34.00 and set a "buy" rating on the stock in a research report on Thursday, February 26th. Morgan Stanley dropped their target price on PROCEPT BioRobotics from $56.00 to $51.00 and set an "overweight" rating on the stock in a research report on Tuesday, December 2nd. Finally, Robert W. Baird assumed coverage on PROCEPT BioRobotics in a research note on Friday. They set a "neutral" rating and a $30.00 price target for the company. Eight investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $40.82.
Get Our Latest Stock Analysis on PRCT
About PROCEPT BioRobotics
(
Get Free Report)
PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company's technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.
The company's flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
